Head-to-head evidence
DB-1303 vs Disitamab Vedotin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: HER2 · full HR+/HER2- Metastatic Breast Cancer pipeline
DB-1303
Developed by DualityBio Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2029 · NCT06827236 (registry estimate)
Disitamab Vedotin
Developed by RemeGen Co., Ltd.
NCT04400695 · Phase 3 · recruiting
This trial randomized 366 patients with HER2-low breast cancer to disitamab vedotin or one of several standard chemotherapy options chosen by their physician, with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Results have not yet been posted to the registry.
Next expected readout: December 2026 · NCT05831878 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DB-1303's landscape · Disitamab Vedotin's landscape